Stocks of Theriva Biologics Inc. (AMEX:TOVX) traded higher last session on Wall Street, up 7.94% to $0.97.
According to the data, Theriva Biologics Inc. (AMEX:TOVX) has 2 analysts covering its stock. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $7.00 and a low of $4.00, we find $5.50. Given the previous closing price of $0.90, this indicates a potential upside of 511.11 percent. TOVX stock price is now 55.13% away from the 50-day moving average and -32.31% away from the 200-day moving average. The market capitalization of the company currently stands at $14.62M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
A total of 0 analysts have issued a hold rating and 2 have given it a buy rating. Brokers who have rated the stock have averaged $5.50 as their price target over the next twelve months.
.
In other news, SHALLCROSS STEVEN A, CEO and CFO bought 25,000 shares of the company’s stock on Jan 20. The stock was bought for $18,705 at an average price of $0.75. Upon completion of the transaction, the CEO and CFO now directly owns 135,000 shares in the company, valued at $0.13 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 29, CEO and CFO SHALLCROSS STEVEN A bought 100,000 shares of the business’s stock. A total of $43,700 was incurred on buying the stock at an average price of $0.44. This leaves the insider owning 110,000 shares of the company worth $0.11 million. A total of 1.21% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TOVX stock. A new stake in Theriva Biologics Inc. shares was purchased by CITADEL ADVISORS LLC during the first quarter worth $55,000. BRIDGEWAY CAPITAL MANAGEMENT, LLC invested $28,000 in shares of TOVX during the first quarter. In the first quarter, VIRTU FINANCIAL LLC acquired a new stake in Theriva Biologics Inc. valued at approximately $12,000. In total, there are 33 active investors with 8.00% ownership of the company’s stock.
Tuesday’s opening bell rang with an opening price of $0.9400 for Theriva Biologics Inc. (AMEX: TOVX). During the past 12 months, Theriva Biologics Inc. has had a low of $0.39 and a high of $4.39. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 4.00, and a quick ratio of 4.00. The fifty day moving average price for TOVX is $0.6266 and a two-hundred day moving average price translates $1.4381 for the stock.
The latest earnings results from Theriva Biologics Inc. (AMEX: TOVX) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.31, beating analysts’ expectations of -$0.35 by 0.04. This compares to -$0.25 EPS in the same period last year. The company reported revenue of $5.01 million for the quarter, compared to $3.27 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 53.1 percent.
Theriva Biologics Inc.(TOVX) Company Profile
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company’s lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.
